Turkey Diagnostics Imaging Market By Type (X-Ray Imaging Solutions, Ultrasound Systems, MRI Systems, CT Scanners, and Nuclear Imaging Solutions), By Mobility (Portable, Standalone), By Source (Domestic, Import), By Application (Cardiology, Oncology, Neurology, Orthopedics, Gastroenterology, Gynecology, Others), By End User (Hospitals & Clinics, Diagnostic Centers, Ambulatory Care Centers, Others),

According to TURKSTAT, Turkey's economy expanded 11% year-on-year in 2021 as per the market standards

According to Turkish Statistical Institute (TurkStat), in 2021, the gross domestic product in Turkey is spending on research and development, with expenditure exceeding around USD802.7 billion and increasing by 42.8%.

Rising prevalence of chronic diseases

According to Turkish Statistical Institute,

Download Free Sample Report

Rising geriatric population’s susceptibility to disease

According to the WHO reports, a Turkish citizen have around 16.8% chance of dying prematurely i.e., before the age of 70 years.

Growing Medical Tourism Infrastructure Development

according to a survey by the Positive Living Association, while the average number of new HIV incident cases has decreased internationally, it has climbed in Turkey, where it went from 0.7 per 100,000 people in 2009 to 3.9 per 100,000 people in 2019.

Market Segmentation

Turkey Diagnostics Imaging Market can be segmented

Market Players

Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.), Siemens Healthcare GmbH, OPKO Health, Inc. (GenPath), Myriad Genetics Inc., NeoGenomics Laboratories, Danaher. (Beckman Coulter, Inc.), Agilent Technologies, Inc., Abcam plc., Bio-Techne. (ExoDx), H.U. Group Holdings, Inc. (Fujeribio) etc.